Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts JL, Thielemans K, Schots R. De Keersmaecker B, et al. Among authors: corthals j. Cancer Immunol Immunother. 2014 Oct;63(10):1023-36. doi: 10.1007/s00262-014-1571-6. Epub 2014 Jun 20. Cancer Immunol Immunother. 2014. PMID: 24947180 Free PMC article.
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.
Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Van Nuffel AM, et al. Among authors: corthals j. Cancer Immunol Immunother. 2012 Jul;61(7):1033-43. doi: 10.1007/s00262-011-1176-2. Epub 2011 Dec 10. Cancer Immunol Immunother. 2012. PMID: 22159452 Free PMC article. Clinical Trial.
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.
Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K. Van Lint S, et al. Among authors: corthals j. Cancer Immunol Immunother. 2014 Sep;63(9):959-67. doi: 10.1007/s00262-014-1558-3. Epub 2014 May 31. Cancer Immunol Immunother. 2014. PMID: 24878889 Free PMC article. Review.
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.
Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Wilgenhof S, et al. Among authors: corthals j. Cancer Immunol Immunother. 2015 Mar;64(3):381-8. doi: 10.1007/s00262-014-1642-8. Epub 2014 Dec 30. Cancer Immunol Immunother. 2015. PMID: 25548092 Free PMC article. Clinical Trial.
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, Neyns B, Thielemans K. De Keersmaecker B, et al. Among authors: corthals j. J Immunother Cancer. 2020 Feb;8(1):e000329. doi: 10.1136/jitc-2019-000329. J Immunother Cancer. 2020. PMID: 32114500 Free PMC article. Clinical Trial.
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. Jansen Y, et al. Among authors: corthals j. Cancer Immunol Immunother. 2020 Dec;69(12):2589-2598. doi: 10.1007/s00262-020-02618-4. Epub 2020 Jun 26. Cancer Immunol Immunother. 2020. PMID: 32591862 Free PMC article. Clinical Trial.
46 results